Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: We conducted a study of chronic therapy with flecainide versus placebo in a small group of LQT‐3 patients with the ΔKPQ deletion to evaluate the safety and efficacy of flecainide in this genetic disorder. In vitro studies have shown that flecainide provides correction of the impaired inactivation associated with the ΔKPQ deletion. Methods:A randomized, double‐blind, placebo‐controlled clinical trial was conducted with flecainide and placebo in six male LQT‐3 subjects with the ΔKPQ deletion. Results:The lowest possible dose of flecainide associated with at least a 40 ms reduction in the QTc interval was determined in an initial open‐label, dose‐ranging investigation using one‐fourth or half of the recommended maximal antiarrhythmic flecainide dose. QTc reduction was achieved with a flecainide dose of 1.5 mg/kg per day in 4 subjects and with 3.0 mg/kg per day in 2 subjects. Subjects were randomized to four 6‐month alternating periods of flecainide and placebo therapy based on the open‐label dose findings. Average QTc values during placebo and flecainide therapies were 534 ms and 503 ms, respectively, with an adjusted reduction in QTc of −27.1 ms (95% confidence interval: −36.8 ms to −17.4 ms; P < 0.001) at a mean flecainide blood level of 0.11 ±0.05 μg/ml. Minimal prolongation in QRS occurred (mean: +2.5 ms), and there were no major adverse cardiac effects. Conclusions:Chronic low‐dose flecainide significantly shortens the QTc interval in LQT‐3 subjects with the ΔKPQ mutation. No major adverse drug effects were observed with flecainide during this trial, but the sample size is not large enough to evaluate the safety of flecainide therapy in patients with this mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
Mohler, P. J., Schott, J.-J., Gramolini, A. O., Dilly, K. W., Guatimosim, S., duBell, W. H., Song, L.-S., Haurogné, K., Kyndt, F., Ali, M. E., et al. (2003) · Nature · doi:10.1038/nature01335 · Cited by 957 · cited 1×
“40; (4) women of child-bearing age not receiving appropriate contraceptive therapy; (5) weight <35 kg; (6) evidence of prior sensitivity to flecainide; (7) renal disease that might adversely effect drug excretion; (8) psychosocial problems that could compromise compliance with the protocol; (9) subjects who live at su…”
Background
Cited by
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
Priori, S. G., Wilde, A. A., Horie, M., Cho, Y., Behr, E. R., Berul, C., Blom, N., Brugada, J., Chiang, C.-E., Huikuri, H., et al. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2013.05.014 · Cited by 1,942
Self-citation(2015) · Europace · doi:10.1093/europace/euv319 · Cited by 1,592
Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., Camm, A. J., Ellinor, P. T., Gollob, M., Hamilton, R., et al. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2011.05.020 · Cited by 1,479
Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., Camm, A. J., Ellinor, P. T., Gollob, M., Hamilton, R., et al. (2011) · Europace · doi:10.1093/europace/eur245 · Cited by 895
Metadata
- Authors
- Moss, A. J., Windle, J. R., Hall, W. J., Zareba, W., Robinson, J. L., McNitt, S., Severski, P., Rosero, S., Daubert, J. P., Qi, M., Cieciorka, M., & Manalan, A. S.
- Venue
- Annals of Noninvasive Electrocardiology
- Publisher
- Wiley
- Published
- 2005-10
- Volume
- 10
- Issue
- s4
- Pages
- 59-66
- ISSN
- 1082-720X (ISSN-L)
- 1542-474X
- OpenAlex
- W2143592728
- Cited by
- 145
- References
- 1
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial. https://app.cochat.ai/papers/10.1111/j.1542-474x.2005.00077.x
- The paper
- Moss, A. J., Windle, J. R., Hall, W. J., Zareba, W., Robinson, J. L., McNitt, S., Severski, P., Rosero, S., Daubert, J. P., Qi, M., Cieciorka, M., & Manalan, A. S. (2005). Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial. Annals of Noninvasive Electrocardiology. https://doi.org/10.1111/j.1542-474x.2005.00077.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.